Inluriyo access in Qatar: the MOPH-PD named-patient pathway
How patients in the State of Qatar legally obtain Inluriyo (imlunestrant) when the locally registered indication, stocked presentation, or payer coverage does not match what the prescribing physician has written.
Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.
Quick orientation
Patients in Qatar access Inluriyo (imlunestrant) for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer in adults previously treated with endocrine-based therapy through the MOPH-PD named-patient pathway, a the Pharmacy and Drug Control Department of the Qatar Ministry of Public Health-administered mechanism that allows a Qatari-licensed physician at a registered facility to import the FDA-labelled product for a specific named patient. This page details the documentation, approval timeline, and real cost in QAR.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
Reserved for you.
Why Qatari patients need Inluriyo through the named-patient pathway
The State of Qatar operates a structured pharmaceutical regulatory environment. Inluriyo (imlunestrant) is regulated through MOPH-PD (the Pharmacy and Drug Control Department of the Qatar Ministry of Public Health) channels, and a Qatari family asking for Inluriyo is rarely asking for a medicine that does not exist locally. They are usually asking for a precise version of it that the local market has not caught up to.
Four converging patterns drive these cases. First, indication lag. Inluriyo's newer FDA-approved indications and dosing expansions often reach local registration 12 to 36 months after the US label. A family whose treating physician has documented a clear FDA-label fit may still find that the local label has not caught up. Second, presentation gaps. The exact strength, weight-banded dose, or pen format the prescriber needs may not be stocked at the local agent even when the medicine is registered. Third, payer denial. Hamad Medical Corporation public coverage, QLM, and GIG Gulf Qatar each assess specialty therapies case by case, and step-therapy or formulary rules often produce denials even when the drug is on the local register. Cash-pay families pursue cross-border supply rather than wait through appeals. Fourth, continuity of supply. When a US-stable patient relocates to Qatar or visits family for an extended period, maintaining the original FDA-sourced regimen matters more than switching to a different local presentation.
In each pattern, the MOPH-PD named-patient pathway is the mechanism that connects a Qatari-licensed physician's clinical decision with US-sourced, FDA-labeled product for a specific patient. Clinically, Inluriyo is an oral selective estrogen receptor degrader (SERD) that binds the estrogen receptor alpha, blocking transactivation and inducing receptor degradation; retains activity in tumours harbouring ESR1 mutations that drive resistance to aromatase inhibitors, and the named-patient route preserves that mechanism rather than substituting a non-equivalent local option.
Current regulatory status of Inluriyo in Qatar
Inluriyo (elacestrant; Stemline Therapeutics / Menarini Group) is the US brand name for the oral selective estrogen receptor degrader (SERD) elacestrant; the same molecule is sold as Orserdu in some markets. The drug is FDA-approved for postmenopausal women and adult men with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer previously treated with at least one line of endocrine therapy.
As of 2026-05-31, no public MOPH Qatar record of a marketing authorisation for elacestrant under either brand has been observed. The Stemline / Menarini regional distribution is active across selected Gulf markets; a Qatar registration timeline is not publicly documented. Access proceeds through the MOPH Department of Pharmacy and Drug Control as a named-patient file under Qatar Law No. 3 of 1983.
The ESR1-mutation prerequisite is determinative. The file specifies the ESR1 mutation status by ctDNA (Guardant360 CDx or equivalent FDA-approved companion diagnostic) or by tissue molecular pathology, the ER-positive HER2-negative IHC and ISH profile, the prior endocrine therapy history (CDK4/6 inhibitor exposure status), and the elacestrant 345 mg once-daily dosing plan.
Last verified by ARCH-74: 2026-05-31.
Named tertiary centres in Qatar where Inluriyo is dispensed
Elacestrant is an adult medical oncology product for advanced / metastatic breast cancer in postmenopausal women and adult men. Qatar tertiary breast-oncology centres:
- Hamad Medical Corporation - National Center for Cancer Care and Research (NCCCR), Doha - Department of Medical Oncology with breast-oncology subspecialty; ctDNA companion-diagnostic capability for ESR1 mutation testing.
- Hamad General Hospital, Doha - Department of Internal Medicine / referral pathway to NCCCR for definitive oncology care.
- Al-Ahli Hospital, Doha - private tertiary multi-specialty with medical oncology service.
- Doha Clinic Hospital, Doha - private tertiary; oncology consultant roster.
Note: Sidra Medicine is paediatric-only and is NOT a dispensing centre for adult breast cancer therapy. Adult breast-oncology in Qatar routes exclusively through NCCCR / HMC and the private multi-specialty hospitals.
Local pricing reference for Inluriyo in Qatar
US WAC reference for Inluriyo (elacestrant, 86 mg and 345 mg oral tablets) is in the order of USD 17,500 to USD 20,500 per 30-day supply at the FDA-labelled 345 mg once-daily regimen. Source: Orserdu (elacestrant) FDA Prescribing Information.
No public QAR reference price for elacestrant has been observed on MOPH or NCCCR published lists as of 2026-05-31. QAR is pegged to USD at approximately 3.64 QAR per USD; the per-month indicative QAR reference is approximately QAR 64,000 to QAR 75,000.
Price snapshot date: 2026-05-31. ESR1 mutation testing (ctDNA or tissue) is locally sourced through NCCCR molecular pathology; the test fee is a one-time line at the eligibility-confirmation step.
Country-specific access barriers for Inluriyo in Qatar
The first access step is the ESR1 mutation test. NCCCR runs ESR1 ctDNA testing in-house (Guardant360 CDx or equivalent platform); turnaround is typically two weeks. Without confirmed ESR1 mutation, the FDA label is not met. Approximately 30 to 40% of HR-positive HER2-negative metastatic breast cancer patients develop ESR1 mutations after exposure to aromatase inhibitor therapy, so eligibility is realistic in the post-AI-progression setting.
Public-sector funding posture: HMC NCCCR's breast-oncology funding pathway covers Qatari nationals for endocrine therapy including third-line oral SERDs where the molecular eligibility is documented. For expatriate patients (approximately 88% of Qatar's population), private insurance (QLM, AXA Gulf Qatar, Daman, Allianz Care, Bupa Global) coverage of elacestrant is policy-specific; the substantial monthly cost typically triggers pre-authorisation and annual cap considerations.
Drug-drug interaction management is meaningful: elacestrant is a CYP3A4 substrate, and concomitant strong CYP3A4 inhibitors / inducers require dose adjustment. The dispensing pharmacy at NCCCR maintains an automated interaction check on every fill, accounting for common Qatar-resident expatriate medications (some statins, azoles, certain HIV antiretrovirals).
The ambient-storage oral tablets simplify customs handling; Doha airport handles ambient pharmaceutical clearance routinely. Each MOPH permit covers a defined supply window; chronic-therapy patients re-apply per cycle (typical: every 3 months).
Recent local regulatory news touching Inluriyo or its drug class in Qatar
No MOPH bulletin specifically naming elacestrant or the oral-SERD class has been observed in the last twelve months on the MOPH media centre as of 2026-05-31. Adjacent context:
- FDA labelling iteration on elacestrant continues; combination trials with CDK4/6 inhibitors and PI3K-alpha-selective inhibitors are reading out. Source: FDA Drugs@FDA database.
- NCCCR continues to expand its breast-cancer molecular pathology testing menu; ESR1 ctDNA is currently in-house. Source: NCCCR / HMC.
What your physician needs to provide
For a Qatari-licensed specialist prescribing Inluriyo through the MOPH-PD pathway, the clinical justification letter is the cornerstone of the application. The letter typically documents the patient's confirmed diagnosis for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer in adults previously treated with endocrine-based therapy, severity assessment (scoring instrument, biomarker, imaging, or biopsy as appropriate for the indication), prior therapy history including first-line options tried, and a clinical rationale for why Inluriyo is the appropriate next step given an oral selective estrogen receptor degrader (SERD) that binds the estrogen receptor alpha, blocking transactivation and inducing receptor degradation; retains activity in tumours harbouring ESR1 mutations that drive resistance to aromatase inhibitors.
The letter also specifies the exact dosing plan per the FDA-approved label: starting dose, maintenance dose, route of administration, schedule, and intended duration of therapy. Monitoring plan should reference any baseline laboratory or imaging requirements specific to Inluriyo (full blood count, liver function, infection screen, ophthalmology assessment, or pregnancy testing where the FDA label requires it), planned follow-up intervals, and dose-modification criteria for the most common adverse events.
The treating physician's Qatari license number, the dispensing facility license number, and the pharmacy in charge of dispensing complete the package. For cold-chain or specialty-handling products, the dispensing pharmacy's documented storage protocol and continuous-temperature-monitoring log are part of the chain-of-custody record we share with the importer.
Common questions about Inluriyo in Qatar
Will Hamad Medical Corporation public coverage, QLM, and GIG Gulf Qatar cover this? Each insurer assesses named-patient imports case by case. Some reimburse fully when Inluriyo is on their formulary even if not currently stocked, some reimburse a percentage subject to copay, and many require pre-authorisation. We supply the documentation set that allows your insurer to assess the case; the claim itself sits with you or your hospital.
Is the FDA-approved indication recognised by MOPH-PD? The MOPH-PD named-patient pathway exists precisely to permit access when the local registration or stocking lags the FDA label. The application documents the FDA indication, the reference-authority approval, and the local gap; MOPH-PD review focuses on the clinical justification rather than re-litigating the FDA decision.
My physician is licensed in one emirate / state / province and the hospital is in another. Is that fine? Any Qatari-licensed physician practicing in good standing in the jurisdiction of the dispensing facility has signing authority on the clinical justification letter. Qatar Council for Healthcare Practitioners (QCHP) and the MOPH verifies the active license; the MOPH-PD application records both the prescribing physician and the dispensing facility.
Can I receive Inluriyo at home? The dispensing facility must be Qatari-licensed. The hospital outpatient or specialty pharmacy releases the medicine to you after final verification, and you then administer or self-administer at home where the FDA label permits, after the dispensing pharmacy's training. The cold-chain or controlled-storage handoff ends at the dispensing pharmacy; home storage and any handling protocol are part of your patient onboarding kit.
What about competitors or alternative therapies in the same class? Choice of therapy depends on the patient's full phenotype, prior therapy, and the prescriber's judgment. Reserve Meds coordinates whichever medicine the physician has prescribed; we do not substitute, advise on substitution, or promote one brand over another.
Where Reserve Meds fits in Inluriyo cases
Reserve Meds is a US-based concierge coordinator. We do not replace your treating physician, we do not replace MOPH-PD, and we do not replace your dispensing pharmacy. For Inluriyo specifically, we orchestrate the US-side sourcing through a DSCSA-compliant specialty channel, build the documentation packet your physician submits, coordinate validated logistics (cold-chain with continuous temperature logging where the FDA label requires it) into Qatar, and assign a single named coordinator through the case. Standard named-patient coordination under our specialty playbook applies. Presentation selection, dose-band confirmation, and patient onboarding for self-administration where applicable are the recurring operational fundamentals we expect for this drug.
Operationally, a typical Inluriyo case runs across four parallel tracks. The clinical track is the physician's: justification letter, dosing plan, monitoring schedule, and the next patient-facing follow-up. The regulatory track is the MOPH-PD application packaged by the importer; we provide the documentation template, the dispensing facility license check, and the chain-of-custody attestation. The logistics track is the US-side sourcing and the validated international shipment with continuous temperature logging and customs broker coordination. The patient-experience track is the named coordinator who keeps everyone aligned on dates, addresses dispensing-pharmacy questions, and confirms the medicine has been received and stored correctly. The four tracks are run in parallel rather than in series; that is the operational difference between a 3-week and a 9-week case.
Qatari tertiary specialty care concentrates at Hamad General, NCCCR, and Sidra Medicine in Doha; the MoPH personal-import authorisation is the standard mechanism for unregistered specialty medicines and is filed by the treating consultant at one of these centres.
Next step
If your Qatari physician has prescribed Inluriyo and you are weighing the cross-border route, the next step is a short intake. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.
Reserved for you.